# Cancer Biological Therapy Market- Top Companies with Size, Trends & Growth 2030 | Credence Research

**The latest market report published by Credence Research, Inc. “Global Cancer Biological Therapy Market: Growth, Future Prospects, and Competitive Analysis, 2023 – 2030.** The global cancer biological therapy market has witnessed rapid growth in recent years and is expected to grow at a **CAGR of 7.5% between 2023 and 2030.** The market was valued at **USD 111945.8 million** in 2022 and is expected to reach **USD 199652.8 million in 2030.**

Cancer biological therapy, also known as immunotherapy or targeted therapy, is a type of treatment for cancer that aims to harness the body's natural immune system or target specific molecules involved in the growth and spread of cancer cells. Unlike traditional treatments like chemotherapy and radiation therapy, which directly attack cancer cells, biological therapy works by stimulating the body's immune response or interfering with specific proteins that promote cancer growth.

**There are two main approaches to cancer biological therapy:**
Immunotherapy: Immunotherapy drugs are designed to enhance the body's immune system's ability to recognize and attack cancer cells. Some common types of immunotherapy include checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines. Checkpoint inhibitors, for example, block certain proteins that inhibit immune responses, allowing the immune system to recognize and attack cancer cells more effectively. CAR-T cell therapy involves modifying a patient's T cells (a type of immune cell) to target cancer cells directly. Cancer vaccines stimulate the immune system to recognize and attack specific cancer-related antigens.

Targeted Therapy: Targeted therapy drugs are designed to interfere with specific molecules or pathways that play a crucial role in cancer growth and progression. These drugs are often used when certain genetic mutations or abnormal proteins are driving the cancer. Targeted therapy is more precise than chemotherapy and can minimize damage to healthy cells. Examples of targeted therapies include tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and hormone therapy.

The choice of which biological therapy to use depends on the type of cancer, its stage, and the patient's individual characteristics, including genetic factors. While biological therapies have shown great promise in treating cancer and have led to significant advancements in cancer care, they may also come with specific side effects and limitations. Patients should discuss the potential benefits and risks of these therapies with their healthcare team to make informed treatment decisions.

**The growth of the cancer biological therapy market worldwide has been influenced by several key factors. These factors have contributed to the expansion of the market and the development of innovative therapies aimed at treating various types of cancer. Here are some of the growth factors that have had a significant impact on the cancer biological therapy market:**

Increasing Cancer Incidence: The rising incidence of cancer globally has driven the demand for effective treatment options. Biological therapies, which target specific molecules involved in cancer growth, have gained prominence due to their potential for personalized and precise treatment.

Advancements in Biotechnology: Progress in biotechnology, particularly in the fields of genomics and proteomics, has led to a better understanding of cancer biology. This has paved the way for the development of targeted biological therapies that can inhibit specific cancer-related pathways.

Immunotherapy Breakthroughs: Immunotherapy, a type of biological therapy that enhances the body's immune system to fight cancer, has witnessed significant breakthroughs. Immune checkpoint inhibitors and CAR-T cell therapies have shown promising results in various cancer types, driving market growth.

Personalized Medicine: The concept of personalized medicine involves tailoring cancer treatment based on the patient's genetic profile and tumor characteristics. This approach has gained traction, leading to the development of more effective and less toxic biological therapies.

**Browse 247 pages report Cancer Biological Therapy Market By Therapeutic Approach (Monoclonal Antibodies (mAbs), Tyrosine Kinase Inhibitors (TKIs), Immune Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Gene Therapy, Oncolytic Viruses, Others) By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Leukemia and Lymphoma, Melanoma, Prostate Cancer, Other Cancer Types) – Growth, Future Prospects & Competitive Analysis, 2023– 2030 – https://www.credenceresearch.com/report/cancer-biological-therapy-market**

**Partnerships in the Cancer Biological Therapy Market:**
• Bristol-Myers Squibb and Celgene Corporation: In 2019, Bristol-Myers Squibb acquired Celgene Corporation. This acquisition was a significant move in the cancer therapy market, as it brought together two major players with a focus on cancer immunotherapy and biological therapies.

• Gilead Sciences and Kite Pharma: Gilead Sciences acquired Kite Pharma in 2017. Kite Pharma is known for its CAR-T cell therapy, which is a revolutionary approach to treating certain types of cancer by modifying a patient's own T-cells.

• Novartis and Spark Therapeutics: Novartis acquired Spark Therapeutics in 2019. This acquisition was part of Novartis' effort to expand its gene therapy portfolio, which has potential applications in cancer treatment.

• Merck and Aduro Biotech: In 2019, Merck entered into a collaboration and acquisition agreement with Aduro Biotech, a company focused on immunotherapy approaches for cancer treatment.

**Acquisitions in the Cancer Biological Therapy Market:**
• Amgen and Onyx Pharmaceuticals: In 2013, Amgen acquired Onyx Pharmaceuticals. Onyx Pharmaceuticals had developed a multiple myeloma drug called Kyprolis, which was a significant addition to Amgen's oncology portfolio.

• Eli Lilly and Loxo Oncology: In 2019, Eli Lilly acquired Loxo Oncology. This acquisition aimed to bolster Eli Lilly's presence in the oncology market, particularly in the field of precision medicine and targeted therapies.

• Pfizer and Array BioPharma: In 2019, Pfizer acquired Array BioPharma, a company known for its research and development in the field of targeted cancer therapies, including BRAF and MEK inhibitors.

• Roche and Genentech: Roche has had a long-standing partnership with Genentech, which it fully acquired in 2009. Genentech has been a pioneer in developing biological therapies for cancer, including monoclonal antibodies like Herceptin and Rituxan.

**Why to Buy This Report-**
• The report provides a qualitative as well as quantitative analysis of the global Cancer Biological Therapy Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.
• The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.
• Major nations in each region with their import/export statistics
• The global Cancer Biological Therapy Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.

**Browse Complete Report- https://www.credenceresearch.com/report/cancer-biological-therapy-market
Visit our Website- https://www.credenceresearch.com
Related Reports- https://www.credenceresearch.com/report/blood-coagulation-testing-market
https://www.credenceresearch.com/report/bone-grafts-and-substitutes-market
Browse Our Blog- https://www.linkedin.com/pulse/cancer-biological-therapy-market-size-trends-analysis-shukla**

**About Us -**
Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.

**Contact Us:**
Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India